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Background: The purpose of the study was to determine the incidence of survivin gene expression in human
granulosa cells during ovarian stimulation in Greek women with normal FSH levels, undergoing IVF or ICSI and
to discover any correlation between levels of gene expression and clinical parameters, efficacy of ovulation or
outcomes of assisted reproduction.
Methods: Twenty nine women underwent ovulation induction for IVF or ICSI and ET with standard GnRH
analogue-recombinant FSH protocol. Infertility causes were male and tubal factor. Cumulus–mature oocyte
complexes were denuded and the granulosa cells were analyzed for each patient separately using quantitative
reverse transcription polymerase chain reaction analysis for survivin gene expression with internal standard the
ABL gene.
Results: The ABL and survivin mRNA were detected in granulosa cells in 93.1%. The expression levels of survivin
were significantly lower in normal women (male infertility factor) compared to women with tubal infertility factor
(p = 0.007). There was no additional statistically significant correlation between levels of survivin expression and
estradiol levels or dosage of FSH for ovulation induction or number of dominant follicles aspirated or number of
retrieved oocytes or embryo grade or clinical pregnancy rates respectively.
Conclusions: High levels of survivin mRNA expression in luteinized granulosa cells in cases with tubal infertility
seem to protect ovaries from follicular apoptosis. A subpopulation of patients with low levels of survivin mRNA in
granulosa cells might benefit with ICSI treatment to bypass possible natural barriers of sperm-oocyte interactions.
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Cells originating from the follicular stratum granulosum
layer differentiate into two types: the cumulus granulosa
cells, which are in physical contact with the developing
oocyte via cytoplasmic projections, and are associated
with the oocyte development and the mural granulosa
cells, which are situated on the theca interna and are* Correspondence: mnvarras@otenet.gr
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reproduction in any medium, provided the oressential for oestrogen production and follicular rupture
[1,2]. In the adult human ovary, there are paracrine
communications between the oocyte and granulosa cells
throughout the growth and development of the oocyte
and the ovarian follicle. Oocytes from primordial follicles
fail to grow in vitro in the absence of granulosa cells.
Cumulus granulosa cells play an important role in regu-
lating oocyte maturation and the oocyte is also an im-
portant modulator of cumulus granulosa cell function
[3]. In the field of assisted reproduction, the selection of
embryos with high implantation potential remains one
of the major goals in order to transfer one embryo andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pregnancies [4]. Studies of gene expression in cumulus
granulosa cells in assisted reproduction treatment (ART)
cycles are attractive non-invasive approaches to evaluate
the fertility potential of the individual oocyte without
compromising the oocyte integrity because any abnor-
mal patterns of gene expression in cumulus cells could
be either causes or consequences of abnormal develop-
ment of the oocyte [3]. In addition, the studies in
humans do not allow direct access to oocytes, while
granulosa cells are easily available since they are always
discarded before ICSI procedures [4].
Apoptosis is the cellular mechanism involved in the
ovarian follicular atresia and luteolysis [5,6]. In the early
stage of follicular development (primordial, primary, and
small preantral), atresia is initiated by oocyte apoptosis
followed by death of the granulosa cells [6,7]. Atresia of
maturing (late preantral, antral) and mature (subordinate
preovulatory) follicles is first demarcated by scattered
granulosa cell apoptosis. As atresia progresses in these
follicles, the number of dying granulosa cells increases
dramatically, and large masses of apoptotic bodies are
shed into the antral space [6,8]. Gonadotropins and
estrogens prevent granulosa cells apoptosis and stimu-
late their mitotic activity, whereas androgens enhance
granulosa cells death by apoptosis [9]. In addition, it has
been found that lanosterol metabolic products regulate
apoptosis during follicular development in mice [10].
Apoptosis of granulosa cells seems to have a negative
effect on IVF outcomes [11-13]. A higher incidence
of apoptotic granulosa cells has been associated with
a higher incidence of empty follicles, fewer oocytes
retrieved, empty follicles, poor quality of oocytes and
embryos development and poor fertilization [11,14]. Fur-
thermore, different ovarian stimulation protocols affect
the incidence of apoptotic granulosa cells differently
[15]. Inhibitor of apoptosis (IAP) proteins can inhibit the
downstream components of the caspase activation path-
ways in the regulation of apoptosis and play important
roles in regulating the progress of apoptosis [16]. A
member of the IAP gene family is survivin which is
located on chromosome 17q25 and encodes a protein,
which is comprised of 142 amino acids, has a molecular
weight of approximately 16.5 kD and is divided into four
exons and three introns. Alternative splicing of the
survivin gene transcript produces a number of different
survivin splice variant mRNAs, which encode different
proteins [17]. Survivin participates in the regulation of
apoptosis by direct or indirect inhibition of the effector
cell death proteases caspase-3 and caspase-7 and regu-
lates the cell cycle in the G2/M phase by associating
with mitotic spindle microtubules [18,19]. Survivin is
abundantly expressed during fetal development, but is
down-regulated in most adult tissues [19-24], except forexpression in normal tissues such as skin, thymus, endo-
thelial cells, proliferative and secretory endometrium
and granulosa cells [20,25-30]. Survivin is, however,
expressed in a wide variety of human cancers, including
stomach, colorectal, lung, breast, pancreatic, prostate,
and non-Hodgkin lymphoma in a prevalence between
30% and 100% [17,19-22,25,31-33]. When analyzed
retrospectively, cancer patients with tumors expressing
survivin exhibited shortened survival, association with
unfavorable markers of disease progression, accelerated
rates of recurrence, and increased resistance to therapy
[20,21]. Johnson et al., (2002) indicated that survivin
could play an important role in granulosa cells, acting as
a functional protein associated with regulation of the cell
cycle and the inhibition of apoptosis [29]. In addition,
Fujino et al., (2008) studied the expression of survivin in
infertile patients and found that the gene expression
levels of survivin in patients with endometriosis were
significantly lower than those in patients with male
factor infertility. The gene expression levels of survivin
in total pregnant patients were higher than those in total
nonpregnant patients and than those in the male factor
infertility [34].
At present, there are no morphological or physio-
logical features of oocytes that can predict whether IVF
fertilization will be successful, or whether is a need for
ICSI [35]. Recently, the use of ICSI in cases unrelated to
male factor infertility has increased greatly at ART facil-
ities [35-37]. Such general use of ICSI, however, raises
concerns because intracytoplasmic sperm injection is
more expensive and time-consuming technique that
requires special equipment and skills. In addition, an in-
crease in the risk of transmitting chromosomal anomal-
ies or imprinting disorders has been described [38-40],
although it is not clear whether these risks are due to
the procedure or to the factors causing male infertility
[35,41]. In view of concept of the beneficial effect of
granulosa cells on oocyte maturation and the need for
independent prognostic markers for better outcomes
with conventional IVF for couples with non-male factor
infertility, we focused on survivin as target genes in
luteinized granulosa cells of the human ovaries.
The purpose of this study was to determine whether
the incidence of survivin expression in human luteinized
follicular granulosa cells shows geographic variations
and whether there is any relationship of the expressed
gene with infertile clinical features and outcomes after
IVF or ICSI and embryo transfer (ET).
Methods
Patient sample
29 women who had been subjected to IVF or ICSI and
ET were enrolled in the study in order to determine the
expression of survivin mRNA in their ovarian follicular
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went IVF due to tubal disease and 10 cases (34.5%)
underwent ICSI due to male infertility. All samples were
acquired from patients that visited the 1st Obstetrics –
Gynecology Department of “Alexandra” General Hos-
pital, Athens during 2011 for assisted reproduction. The
patients were subjected to the same ovulation protocol.
Written informed consent was obtained from the parti-
cipants of this study. Women with history of diabetes
mellitus and/or polycystic ovarian syndrome (PCOS), as
well as women with endometriosis were excluded from
the study.
Hormone assays
The hormone levels were evaluated using radio-
immunoassay (RIA) commercially available kits. Levels
of FSH, LH, oestradiol and Antimüllerian hormone
(AMH) were determined at the 2nd to 5th day of the
menstrual cycle. Serum prolactine (PRL) levels were
also determined within one of the six previous men-
strual cycles. Also, serum oestradiol levels were mea-
sured on the 5th day of rFSH administration and on the
day of hCG administration.
Protocol for controlled ovarian hyperstimulation and
follicle monitoring
Commercially available GnRH-analogue (Suprefact,
Buserelin; Hoechst, Frankfurt, Germany) was self-
administered subcutaneously (sc) into the thigh at a
dose of 200 μg/day, starting on the midluteal phase of
the preceding menstruation cycle and continuing until
24 h before the administration of hCG. Treatment with
rFSH (Gonal-F; Serono, Geneva, Switzerland) was
started after 14 days with 225 IU/day and continued
until the administration of hCG for ovulation induc-
tion. Serum oestradiol and ovarian suppression were
evaluated prior to the administration of the exogenous
gonadotropins. rFSH dose was administered as a sc in-
jection in the abdomen and readjusted upon response,
based on ultrasound and serum E2 levels, with a max-
imum does of 450 IU/day. The dose was reduced or
discontinued if the patient was at risk of developing
OHSS. Ovulation was induced with 10,000 IU of hCG
within 24 h after the last rFSH and GnRH-a administra-
tion, preferably when all of the following criteria had
been met: the largest follicle had reached a mean diam-
eter of at least 18 mm, 2 or more other follicles had a
mean diameter of 16 mm, and serum estradiol (E2)
levels were within an acceptable range for the number
of follicles present. All follicles of >10 mm in diameter
were retrieved with follicle aspiration 36 hours after
hCG injection by transvaginal ultrasound-guided aspir-
ation. Maturity of oocytes was assessed by microscopic
examination. An oocyte found at least in the metaphaseII stage (MII) (production of one polar body) was con-
sidered as a mature.
In the case of IVF, insemination was withheld with in-
semination medium 6 hours after oocyte retrieval, and
fertilization was confirmed by identification of pronuclei
16 hours after insemination. The participating patients
of this group gave written consent some of the cumu-
lus–mature oocyte complexes (CMOCs) to be used only
for the study: the cumulus–mature oocyte complexes
(CMOCs) were manually denuded separately using a
fire-polished tip glass pipette, these granulosa cells were
analyzed for each patient separately, but the correspond-
ing mature oocytes were not used for fertilization.
In case of ICSI, the cumulus-mature oocytes com-
plexes (CMOCs) were manually denuded from granu-
losa cells using a fire-polished tip glass pipette.
Granulosa cells from all mature oocytes per patient
were collected together. ICSI was performed only in
oocytes that were morphologically confirmed to be in
metaphase II with the first polar body extruded (mature
oocytes). Motile spermatozoa were selected with the
swim-up technique, which consists of washing the
semen with the Gamete medium and centrifugation at
300 g. The supernatant was discharged and in the same
tube 1 ml of the medium was added and left standing
for 30 min to allow the sperm to swim up from the
pellet. Just before fertilization 2 μL of the sperm sus-
pension were added to 5 μL of Polyvinylpyrrolidone so-
lution (PVP) in order to reduce the spermatozoa
mobility. A single spermatozoon was retrieved and
injected to the cytoplasm of the oocyte through the
zona pellucida. The fertilized oocytes were placed in
plates with 1 mL of IVF nutrient and were observed
using stereomicroscope 16 to 18 hours later for the
presence of pronuclei and polar bodies.
Fertilization was considered normal when the oocytes
contained two pronuclei (2PN)/two polar body stage
(2PN/2 PB) 16 hours after fertilization. Three embryos
were replaced in the uterine cavity on day 2 or 3 after
fertilization. Micronized progesterone (P4) (Utrogestan,
Faran, Greece) (200 mg three times daily) was adminis-
tered by the vaginal route as luteal phase support,
starting after oocyte collection and continued until
menses or during the first three weeks of pregnancy.
P4 treatment was continued up to menstruation or for
at least the first 3 weeks if the patient became preg-
nant. Definition of pregnancy required a positive β-
hCG test 14 days after embryo transfer. Definition of a
clinical pregnancy required an endometrial gestational
sac with a transvaginal ultrasound scan, which contin-
ued the development until at least the twelfth gesta-
tional week. At the midluteal phase, careful abdominal
ultrasound assessment was performed to record any
signs of OHSS. The patient then was followed up, and
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recorded.
Evaluated parameters
For the patients enrolled in the study the following char-
acteristics were recorded: age, body mass index (BMI),
duration of infertility, previous assisted reproduction
attempts, serum base levels of FSH and LH and Anti-
müllerian hormone (AMH) levels at the beginning of
the menstrual circle, as well as serum prolactine (PRL)
in one of the past 6 menstrual cycles. Parameters asso-
ciated with ovulation stimulation were also recorded:
total duration of ovulation stimulation (days), total dose
of rFSH used and serum beta-oestradiol levels on the
day of hCG administration. Moreover, we kept records
of the number of follicles aspirated and the total number
of oocytes retrieved. Evaluated parameters associated
with oocyte developmental competence included: (i)
the number of mature oocytes found in metaphase II
(MII), (ii) the oocyte maturation rate, (iii) the rate of
fertilization as the ratio of two pronuclei observed 16-
18 h after semen administration by the number of intact
oocytes after IVF or ICSI (2PN) and the 7-cell stage on
day 3, (iv) the degree of fragmentation in embryos, and
the ratio of good quality embryos as the ratio of embryos
with at least 7 cells and <10 % fragmentation on day 3
after IVF or ICSI, (grade 1 to grade 3). All the above
parameters, as well as the outcome of IVF or ICSI (clin-
ical pregnancy, biochemical pregnancy, failure to induce
pregnancy) were evaluated in association with survivin
mRNA expression.
RNA isolation and preparation of cDNA from granulosa
cells
In order to determine survivin mRNA expression, cumu-
lus cells were collected during oocyte retrieval. The cells
were segregated from cumulus-mature oocyte complexes
(CMOCs) through the process of stripping using a fire-
polished tip glass pipette. RNA was extracted using the
RNeasy Micro Kit (Qiagen, Valencia, CA, USA). RNA
extraction was conducted according to manufacturer’s
protocol. The extracted RNA was a product of cumulus
cells pooled from several CMOCs and not only from the
oocytes that proceeded to embryo transfer. Moreover,
RNA concentration of each sample was determined by
spectrophotometry and its quality was evaluated by agar-
ose gel electrophoresis. cDNA preparation was per-
formed using 20 ng aliquots of total RNA extracted.
RNA was reverse-transcribed using 0.5 mM dNTP mix
(Ambion, Austin, Tx, USA), 5 μM oligo dT Primer
(Ambion, Austin, Tx, USA), 1xRT buffer (Ambion, Aus-
tin, Tx, USA), 80 U ribonuclease inhibitor (Invitrogen
Life Technologies), 1600 U M-MLV reverse transcriptase
(Invitrogen Life Technologies) and nuclease free water(Ambion, Austin, Tx, USA) to a total volume of 40 μl.
The reactions were carried out in Mastercycler (Eppen-
dorf ) with the following conditions: 80°C for 3 min, 42°
C for 60 min and 92°C for 10 min. The resulting cDNAs
were stored at -20°C.Quantitative real time-polymerase chain reaction analysis
The expression of ABL and survivin mRNA in luteinized
granulosa cells were assessed by real-time PCR using
sense and antisense primer pairs and hybridization
probes for the genes of interest as described by Emig M,
et al. [42] for ABL, and by Steffen et al. [43] for survivin
generating a 338 and 379 base pair products respectively.
The primers of each set were intended to bind to differ-
ent exons to avoid amplification of contaminating
genomic DNA and to eliminate mis-priming events gen-
erating detectable signal. The specific primers and
probes were used at a concentration of 0.5 μl and 0.5 μl
in each reaction respectively. To determine the steady
amount for survivin mRNA levels in granulosa cells, a
quantitative competitive PCR (QC RT-PCRE) was devel-
oped using a LightCycler 480 (Roche). All samples were
run in duplicate and no template controls were included
in all runs to exclude possible DNA contaminations. Re-
action volume was 20 μl and carried out with 2x master-
mix (QuantiTect Multiplex PCR Master Mix, Qiagen,
Berlin, Germany) 10 μl, 10pmol of each 30 and 50 primer
(TIB MolBiol, Berlin, Germany) 0.5 μl, 5pmol of each
probe (TIB MolBiol, Berlin, Germany) 0.25 μl, 2 μl
cDNA (from 1 μg RNA) and adjusted to 20 μl reaction
final volume with ddH2O. Then mixes were incubated in
the Light Cycler instrument (Roche Molecular Systems,
Alameda, CA). Forty-five cycles of PCR amplification
were run with 95°C for 15 s for denaturation, 64°C for
annealing 30 s, and 72°C for 20 s for extension. Melting
curve experiments had previously established that the
fluorescence signal for each amplicon was derived from
the products only, and no primers dimmers were found.Statistical analyses
All statistical analyses were performed using the SATA
9 statistical software. Differences between qualitative/
categorical variables were evaluated with the x2 of Pear-
son. Non-parametric Wilcoxon rank-sum and Kruskal-
Wallis tests were used to compare differences of quantita-
tive variables between categories of qualitative variables.
The Spearman rank correlation coefficient (Spearman’s
rho) was used to analyze the relationship between two
different values. Multiple linear regression analysis and
multiple logistic regression analysis were used for the
detection of parameters related with the levels of survi-
vin gene expression. A p value <0.05 was considered
statistically significant.
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Patients' characteristics
The average age of the patients was 36.03 ± 4.75 years,
their average BMI was 22.86 ± 4.04, the average basal
FSH levels (IU/l) were 6.59 ±2.06, and the average pro-
lactin (PRL) levels (ng/ml) were 13.92 ± 6.73. Table 1
presents additional demographic and clinical parameters.
No statistically significant differences were found be-
tween tubal or male factor infertility and age of women,
prolactin levels, estradiol levels on the fifth day of rFSH
administration and the number of oocytes retrieved
(Table 2).
Fertilization was successful in all cases in the labora-
tory (29/29). A pregnancy test was positive in 31%
(n = 9) of cases and a clinical pregnancy was confirmed
in 21% (n = 6) of women. No multiple pregnancies were
observed, while a biochemical pregnancy, a first tri-
mester abortion and an ectopic pregnancy occurred in
1 case each. Positive pregnancy test was found in 4
cases in the ICSI group and in 5 cases in the IVF
group. Clinical pregnancy was found in 3 cases in each
group. The median for age in the ICSI group was 36.5
(IQR: 33.0-39.0), while in the IVF group was 36.0
(IQR: 33.0-37.0). The median for PRL in the ICSI
group was 12.7 (IQR: 7.2-17.0) and in the IVF group
was 14.7 (IQR: 9.0-16.6). The median for estradiol
levels (pg/ml) the fifth day of rFSH administration in
the ICSI group was 321.5 (IQR: 300.0-498.0), while in
the IVF group was 450.0 (IQR: 267.0-758.0). The me-
dian number of oocytes retrieved in the ICSI group
was 8.5 (IQR: 6.0-10.0), while in the IVF group was 8.0
(IQR: 6.0-10.0).
Incidence of survivin gene expression in granulosa cells
Survivin gene expression in luteinized granulosa cells in
women that underwent IVF or ICSI was observed in







Serum estradiol on the 5th day of rFSH administration (pg/ml)
Serum estradiol on the day of hCG administration (pg/ml)
Number of follicles aspirated
Grade 2 embryos
Grade 3 embryos
High quality embryo ratio (%)
Patients’ demographics and clinical parameters.survivin mRNA/ABL mRNA level was 0.45 (quartile
range 0.22 – 2.94).
Expression of survivin gene in granulosa cells according
to clinical parameters
Higher levels of survivin gene expression were found in
the cases with tubal factor infertility compared to nor-
mal women (male factor infertility) (Wilcoxon rank-sum
test, p = 0.007) (Figure 1). Also, it is obvious that the
same statistical significance was found between IVF and
ICSI method of treatment, respectively. There were no
significant differences among the levels of survivin gene
expression and age, BMI, years and causes of infertility,
previous assisted reproduction attempts, basal serum
FSH and LH levels, serum levels of PRL and AMH,
serum oestradiol levels on the fifth day of rFSH adminis-
tration and on the day of hCG administration, the total
dose of rFSH, the duration of treatment, the number of
follicles aspirated, the total number of oocytes retrieved,
the number of mature oocytes retrieved, the mature
oocytes ratio (<60%, 60-75% and ≥75%), the embryo
grade, the positive pregnancy test and the existence of
clinical pregnancy.
When embryo grade (grade 3, grade 3 + 2, grade 2)
was used as the dependent variable, whereas age (ys),
PRL (ng/ml), estradiol levels the fifth day of rFSH ad-
ministration (pg/ml) and survivin/ABL mRNA expres-
sion were used as independent variables, only estradiol
levels on the fifth day of rFSH administration showed a
trend for correlation to the embryo grade, however it
did not reach statistical significance (p = 0.087) (Table 3).
Additionally, when the clinical pregnancy was used as
dependent variables and the above parameters as inde-
pendent variables no correlations were found respect-
ively. Only a trend for correlation but not statistically
significant was found between clinical pregnancy and












Table 2 Infertility causes cycle characteristics
Infertility causes Male factor Tubal factor p value*
Age (years) 36.50 (33.00, 39.00) 36.00 (33.00, 37.00) 0.564
PRL (ng/ml) 12.7 (7.2, 17.0) 14.70 (9.00, 16.60) 0.920
Estradiol, 5th day of rFSH administration (pg/mL) 321.50 (300.00, 498.00) 450.00 (267.00, 758.00) 0.251
Number of oocytes retrieved 8.50 (6.00, 10.00) 8.00 (6.00, 10.00) 0.693
*Statistical test.
Male or tubal infertility causes in correlation with patients’ cycle characteristics.
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were used as dependent variable, whereas age (ys), BMI,
peak levels of estradiol the day of hCG administrion,
number of oocytes retrieved, mature oocyte ratio and
total dose of rFSH administrated were as independent
variables, but this analysis yielded no statistically signifi-
cant results.
Discussion
Apoptosis is a genetically determined and biologically
functional mode of cell death. It plays important roles
in numerous physiological events in mammals, includ-
ing ovarian follicular atresia, decidualisation and pla-
centation during embryo implantation, as well as many
pathological conditions [44,45]. The major features of
apoptosis are internucleosomal DNA fragmentation,
cell shrinkage, plasma membrane blebbing, formation
of apoptotic bodies and phagocytosis of apoptotic bod-
ies by macrophages [46]. During follicular growth,
more than 99% of follicles disappear, primarily due to
apoptosis of granulosa cells. Follicular atresia is a hor-
monally regulated process, and different factors are
affecting the decision to die at different stages ofFigure 1 Higher levels of survivin gene expression are shown in case
factor infertility) (Wilcoxon rank-sum test, p = 0.007).ovarian follicle development [47]. Atretogenic factors
include caspases, protein bax, members of the tumor
necrosis factor family (TNF-α, Fas, FasL, TRAIL),
tumor suppressor protein P53, members of transform-
ing growth factor-beta family (factor NODAL and
AMH), c-Myc, endothelins, androgens and GnRH [44].
Successful follicle development depends on the pres-
ence of survival factors that promote follicle growth
and also protect cells from apoptosis. These include
factors produced within the ovary as well as the gona-
dotropins LH and FSH. Some of the paracrine factors
that promote survival during the growth and differenti-
ation of follicles include kinase Akt, members of bcl-2
family, KIT-ligand and c-KIT receptors, stem cell factor
(SCF), members of TGF-beta family (activin, factors
BMP-4 and BMP-7, growth differention factor-9), oes-
trogens, insulin and IGFs, epidermal growth factor
(EGF), basic fibroblast growth factor (bFGF), TGF-α,
interleukin 1b (IL-1b), growth hormone (GH) and the
member of inhibitor of apoptosis, survivin [44,47,48].
Most of the inhibitors of follicle atresia are regulated
by FSH and LH. When the growing follicles reach the
antral stage, they express receptors for FSH ands with tubal factor infertility compared to normal women (male
Table 3 Embryo grade cycle characteristics
Characteristics Embryo grade p value*
Grade 3 Grade 3+ 2 Grade 2
Age (years) 36.00 (35.00, 37.00) 38.00 (36.00, 41.00) 32.50 (29.50, 35.00) 0.178
FSH (IU/L) 6.00 (4.90, 7.50) 9.40 (5.50, 9.80) 6.30 (6.20, 7.20) 0.402
PRL (ng/mL) 12.10 (9.00, 16.60) 13.90 (4.80, 22.30) 14.90 (9.40, 16.60) 0.974
Total gonadotropin dosage 2,800.00 (2,300.00, 3,400.00) 2,550.00 (1,700.00, 3,075.00) 3,837.50 (2,837.50, 4,025.00) 0.197
Estradiol, 5th day of rFSH administration (pg/mL) 474.00 (306.50, 697.50) 401.00 (300.00, 509.00) 233.00 (110.00, 321.50) 0.087
Estradiol, peak (pg/mL) 2,062.50 (1,630.50, 2,593.00) 1570.00 (1,254.00, 2,795.00) 1,925.00 (1,425.50, 2,034.00) 0.706
Number of oocytes retrieved 9.00 (6.50, 10.00) 7.00 (5.00, 10.00) 8.00 (6.00, 8.50) 0.713
Mature oocyte ratio (%) 67.00 (61.50, 78.00) 80.00 (70.00, 91.00) 75.00 (62.50, 76.50) 0.504
Survivin/ABL 0.60 (0.30, 3.10) 0.20 (0.00, 2.50) 0.20 (0.10, 0.50) 0.153
*Statistical Test.
Embryo grade in correlation with patients’ cycle characteristics and survivin/ABL genes expression.
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concentrations are critical for survival of follicles that
have differentiated to the antral stage or beyond. Dur-
ing each reproductive cycle, increasing FSH concentra-
tions rescue developing follicles. LH is important for
follicles approaching ovulation and expressing LH re-
ceptor [47]. FSH and LH influence oocyte growth and
maturation through the sterol pathways in mice [49].
Follicular fluid meiosis-activating sterol (FF-MAS) is
found at high concentrations in the follicular fluid of
mammals including humans in response to gonadotro-
pins and is proved to be stimulatory to oocyte meiotic
resumption, while lanosterol 14α-demethylase (LDM),
a key enzyme that converts lanosterol to FF-MAS
seems to have a positive effect on the oocyte plasma
maturation for fertilization and early embryo develop-
ment in mice [50]. In addition, epidermal growth factor
receptor (EGFR) activation, by protein kinase C (PKC)
signal pathway, participates in FSH-induced oocyte




Age (years) 36.00 (33.00, 37
FSH (IU/L) 6.3 (5.50, 7.90)
PRL (ng/mL) 12.10 (7.20, 16.1
Total gonadotropin dosage 3,075.00 (2,275.0
Estradiol, 5th day of rFSH administration (pg/mL) 400.00 (252.00,
Estradiol, peak (pg/mL) 2,022.00 (1,561.0
Number of oocytes retrieved 8.00 (6.00, 10.00
Mature oocyte ratio (%) 71.00 (60.00, 78
Survivin/ABL 0.50 (0.20, 3.00)
*Statistical Test.
Clinical pregnancy in correlation with patients’ cycle characteristics and survivin/ABexpression of the LH receptor (LHR) in cumulus cells
is related with FSH-induced meiotic resumption of cu-
mulus enclosed oocytes (CEOs). An important new
step towards understanding the physiological actions of
gonadotropins during oocyte maturation is the finding
that in mice the LHR expression in cumulus cells has a
functional role during FSH-induced oocyte maturation,
which process is possibly regulated by MAPK cascade
[52]. In addition to all that it has been found that in
mice FSH increases cAMP-dependent protein kinase
(PKA) levels and induces cAMP response element-
binding protein (CREB) phosphorylation and cyto-
chrome P450 lanosterol 14α-demethylase (CYP51) ex-
pression in cumulus cells before the oocyte meiotic
resumption [53]. In the absence of survival factors, en-
dogenous apoptosis pathways within the follicle be-
come activated and lead to follicular atresia [47]. The
present study showed the expression of survivin in
luteinized granulosa cells from a sample of Greek
patients that underwent IVF or ICSI. To the best ofClinical pregnancy
Yes p value*
Median [IQR]
.00) 38.00 (36.00, 44.00) 0.069
5.5 (4.10, 8.50) 0.634
) 19.20 (11.70, 22.60) 0.054
0, 3,675.00) 2,625.00 (2,325.00, 3,175.00) 0.398
691.00) 450.00 (309.00, 509.00) 0.572
0, 2,569.00) 2,188.50 (1,254.00, 2,805.00) 0.686
) 9.00 (6.00, 10.00) 0.765
.00) 68.50 (67.00, 83.00) 1.000
0.3 (0.20, 1.20) 0.246
L genes expression.
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mined the frequency of survivin expression in these
cells from a sample of Greek patients. Therefore, the
present study gives an additional estimation on the fre-
quency of expression of the survivin in luteinized gran-
ulosa cells, which is detected in almost all of the
studied cases from Greek patients. However, more
studies are needed to analyze larger numbers from
Greek patients and investigate therefore whether geo-
graphic or ethnic prevalence of survivin gene expres-
sion could be caused by environmental or genetic
factors. The expression of survivin, in granulosa cells
reported herein, is in agreement with the previous find-
ings from Fujino et al. [34], who studied the expression
of survivin gene expression in granulosa cells from in-
fertile Japanese patients and found such expression in
all granulosa cells. In addition, the present study found
a statistically significant increased expression of survi-
vin in granulosa cells of women who had tubal factor
infertility compared with normal women (male factor
infertility). This finding suggests a protective role of
survivin in the ovarian microenvironment from situa-
tions such as inflammation (salpingitis), hydrosalpinx,
tubal ligation and salpingectomy. Ovrieto et al., (2011)
studied the effects of salpingectomy due to hydrosal-
pinx on the outcomes of assisted reproduction and
embryo transfer and found a significant reduction in
ipsilateral ovarian response to ovulation induction as
regards the development of follicles [54]. It is therefore
likely that survivin might try to protect the ovaries,
with possible influenced perfusion due to the ipsilateral
salpingectomy. In cases with tubal inflammation or
hydrosalpinges survivin might try to protect the ovaries
from follicular apoptosis in a paracrine environment.
However, more studies are needed to support our hy-
pothesis probably using animal models.
In the present study the capacity for fertilization (ferti-
lizability) was 100%, regardless IVF or ICSI method
used. An increased survivin expression in granulosa cells
was found in women undergoing IVF compared with
ICSI. Nakahara et al., (1997) suggested that when the
quality of eggs is small, measured by apoptosis in granu-
losa cells, then the eggs are more likely to be fertilized
by ICSI compared with IVF method [11]. However, Cla-
vero et al., (2003) found that the rate of apoptosis in
granulosa cells was not associated with the maturity of
the oocytes and the ability for fertilization in ICSI or the
quality of follicles during the ovulation induction [55].
Despite the controversy that exists in the literature
about the effects of apoptosis in luteinized granulosa
cells as predictor of oocytes quality during ovulation in-
duction in cycles of IVF or ICSI, the estimation of sur-
vival factors in these cells might have prognostic role.
An example supporting the validity of using survivalfactors for prognosis provides the IGFs family. It has
been found that the IGF1, IGF2 and their receptors are
down regulated in ovarian granulosa cells of women
with diminished ovarian reserve (DOR) compared to
those with normal ovarian reserve (NOR) undergoing
in vitro fertilization (IVF) [56]. However, more research
is needed about the clinical significance of the expres-
sion of some other survival factors in the luteinized
granulosa cells. Data generated using mice genetic mod-
els perturbing ovulation and fertility indicates that the
EGF-like growth factors amphiregulin, epiregulin, and
betacellulin are induced by LH and activate the EGF re-
ceptor pathway in granulosa cells of preovulatory folli-
cles to impact ovulation [57,58]. Whether this network
also plays a critical role in humans and whether it can
be used as a biological marker of follicle development or
for the improvement of fertility remains to be deter-
mined [57]. We enounce our hypothesis about the levels
of survivin mRNA expression in ovarian granulosa cells
in tubal factor infertility. Some patients in the subpopu-
lation of women with tubal factor undergoing assisted
reproduction and embryo transfer probably could benefit
in assessing oocyte quality by measuring the levels of
survivin expression in their granulosa cells. Therefore, if
the survivin levels in granulosa cells are low, then ICSI
should be concerned, as ICSI is an invasive method and
good oocyte quality is not required. On the other hand,
if survivin levels are highly expressed in granulosa cells
then IVF should be preferred, as IVF is a non-invasive
method and therefore normal sperm-egg interaction and
good oocyte quality is essential. However, the cut-off
survivin mRNA expressed levels have to be determined
in such cases. Fujino et al., (2008) found that there was a
statistically significant correlation in the levels of survi-
vin expression in granulosa cells among women with
endometriosis and normal women. In women with
endometriosis lower survivin levels were found [34].
However, one factor to be considered is that in the
present study only normal women (male factor infertil-
ity) and women with tubal factor infertility were studied.
Women with endometriosis were not included since
endometriosis promotes apoptosis [11]. Also, in the
present study women with polycystic ovarian syndrome
were not included because androgens promote apop-
tosis. Fujino at el, (2008) found no statistically significant
difference in levels of survivin expression between nor-
mal women (male factor infertility) and women with
tubal factor infertility [34], as we found in this study.
Fujino et al., (2008) found that the survivin expression in
granulosa cells was higher in all pregnant women than
in not pregnant women [34]. However, this did not re-
sult from the findings of this study. As there is some
controversy in this field more studies should be taken.
In addition, it would be interest further studies to
Varras et al. Reproductive Biology and Endocrinology 2012, 10:74 Page 9 of 10
http://www.rbej.com/content/10/1/74investigate expression with any clinical significance of
survivin gene in granulosa cells of patients with dimin-
ished ovarian reserve (DOR) as such population was not
included in our study.Conclusions
There is an expression of survivin gene in luteinized
granulosa cells at a ratio of 93% in cases from Greek
patients. Higher levels of survivin mRNA expression in
luteinized granulosa cells in cases with tubal infertility
compared to normal women seem to protect ovaries
from follicular apoptosis in a paracrine environment in
cases with tubal inflammation or hydrosalpinges or in a
reduced ovarian perfusion environment in cases with ip-
silateral salpingectomies. It seems that a subpopulation
of patients with lower levels of survivin mRNA in granu-
losa cells during the assisted reproduction treatment
might benefit with ICSI, which is an invasive method
and therefore no good oocyte quality is required.
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